1. Show article details.

    CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference

    GlobeNewswire – 7:30 AM ET 10/22/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen (OCGN), will speak on the importance of strategic partnerships in gene therapy including product consistency, identifying the right partner as well as providing examples of su...

  2. Show article details.

    Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

    GlobeNewswire – 7:30 AM ET 10/16/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.

  3. Show article details.

    BRIEF-Ocugen Engages Kemwell Biopharma For cGMP Manufacture Of OCU200

    Reuters – 7:34 AM ET 10/06/2020

    Ocugen Inc (OCGN): * OCUGEN ENGAGES KEMWELL BIOPHARMA FOR CGMP MANUFACTURE OF OCU200 Source text for Eikon: Further company coverage:

  4. Show article details.

    Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

    GlobeNewswire – 7:30 AM ET 10/06/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it has entered into an agreement with Kemwell Biopharma Pvt.

  5. Show article details.

    Ocugen to Participate in a Virtual Fireside Chat at the Chardan Genetic Medicines Conference

    GlobeNewswire – 7:35 AM ET 09/29/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will participate in a Virtual Fireside Chat during the Chardan Genetic Medicines Conference on October 6th at 9 a.m. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder along with Dr. Mohamed Genead, M.D., Acting Chief Medical ...

  6. Show article details.

    Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    GlobeNewswire – 7:30 AM ET 09/16/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 1:40 p.m. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of O...

  7. Show article details.

    BRIEF-Ocugen Granted 180-Day Extension By Nasdaq To Regain Compliance With Bid Price Rule

    Reuters – 4:26 PM ET 09/08/2020

    Ocugen Inc (OCGN): PLIANCE WITH BID PRICE RULE Source text for Eikon: Further company coverage:

  8. Show article details.

    Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

    GlobeNewswire – 4:25 PM ET 09/08/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that the Company received a letter from the Listing Qualification Department of The NASDAQ Capital Market notifying that Ocugen (OCGN) has been granted an additional 180-day compliance period or until March 8, 2021, to regain compliance ...

  9. Show article details.

    Ocugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

    GlobeNewswire – 7:30 AM ET 09/03/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 3 p.m. ET.

  10. Show article details.

    BRIEF-Ocugen Says U.S. Patent And Trademark Office Issued Patent To Co

    Reuters – 4:16 PM ET 08/31/2020

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - ON AUGUST 25, U.S. PATENT AND TRADEMARK OFFICE ISSUED PATENT TO CO. * Ocugen Inc (OCGN) - PATENT RELATES TO OCU300 AND OCU310, TWO PRODUCT CANDIDATES THAT COMPANY HAD PREVIOUSLY BEEN DEVELOPING. * Ocugen Inc (OCGN) - NOT CURRENTLY DEVELOPING ANY THERAPIES RELATED TO PATENT Source : Further company coverage:

  11. Show article details.

    Ocugen to Present at the LD 500 Virtual Investor Conference

    GlobeNewswire – 7:40 AM ET 08/28/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the LD 500 Virtual Investor Conference on Friday, September 4 at 11 a.m. ET.

  12. Show article details.

    BRIEF-Ocugen Entered Into An At Market Issuance Sales Agreement

    Reuters – 7:33 AM ET 08/17/2020

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - ON AUGUST 14, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT. * Ocugen Inc (OCGN) - PURSUANT TO AGREEMENT CO MAY ISSUE & SELL SHARES OF ITS COMMON STOCK HAVING GROSS SALES PRICE OF UP TO $30.0 MILLION Source: Further company coverage:

  13. Show article details.

    BRIEF-Ocugen Reports Q2 Loss Per Share $0.19

    Reuters – 8:03 AM ET 08/14/2020

    Ocugen Inc (OCGN): * Q2 LOSS PER SHARE $0.19. * CASH, CASH EQUIVALENTS AND RESTRICTED CASH TOTALED $15.1 MILLION AS OF JUNE 30, 2020, VERSUS $7.6 MILLION AS OF DECEMBER 31, 2019. * QTRLY LOSS PER SHARE $0.19. * Q2 EARNINGS PER SHARE VIEW $-0.04 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  14. Show article details.

    Ocugen Provides Business Update and Second Quarter 2020 Financial Results

    GlobeNewswire – 7:30 AM ET 08/14/2020

    Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8:30 a.m. ET Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to cure blindness diseases, today reported second quarter 2020 financial results along with a general business update.

  15. Show article details.

    BRIEF-Ocugen Receives FDA Orphan Drug Designation Ocu400 (Aav-Nr2e3) Gene Therapy For Pde6b Gene Mutation-Associated Retinal Diseases

    Reuters – 9:29 AM ET 08/10/2020

    Ocugen Inc (OCGN): * OCUGEN RECEIVES FOURTH FDA ORPHAN DRUG DESIGNATION FOR THE SAME PRODUCT, OCU400 GENE THERAPY, FOR THE TREATMENT OF ANOTHER KEY INHERITED RETINAL DISEASE, PDE6B GENE MUTATION-ASSOCIATED RETINAL DISEASES Source text for Eikon: Further company coverage:

  16. Show article details.

    Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

    GlobeNewswire – 7:30 AM ET 08/10/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced the U.S. Food and Drug Administration granted the fourth Orphan Drug Designation for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases.

  17. Show article details.

    Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

    GlobeNewswire – 1:45 PM ET 08/06/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will host a conference call to discuss its Q2 2020 financial results and provide a business update at 8:30 a.m. on Friday, August 14, 2020. The company will issue a pre-market earnings announcement the same day.

  18. Show article details.

    Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

    GlobeNewswire – 7:30 AM ET 07/27/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced the U.S. Food and Drug Administration granted the third Orphan Drug Designation for OCU400 in the treatment of RHO mutation-associated retinal degeneration.

  19. Show article details.

    Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

    GlobeNewswire – 5:15 PM ET 07/21/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug Congress USA 2020 Conference, to be held virtually from August 24-27, 2020.

  20. Show article details.

    Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

    GlobeNewswire – 8:30 AM ET 06/03/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases, today announced the appointment of Dr. Mohamed Genead as chair of the Ocugen (OCGN), Inc. Retina Scientific Advisory Board, which is comprised of prominent experts who provide strategic advice, clinical and regulatory support, and scientific...

Page:

Today's and Upcoming Events

  • Nov
    06

    OCGN to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    14

    OCGN announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.